A versatile intracorporeal ventricular assist device based on the Thoratec VAD system

Reichenbach, Steven H.; Farrar, David J.; Hill, J. Donald

doi:10.1016/s0003-4975(00)02616-3

Cited by 33 publications

(19 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, this is not significantly different from data on BVAD patients in the literature, because the recent INTERMACS annual report published a 6-month survival rate of 50% for BVAD patients. 4 We consider the advantages of an implantable biventricular system to lie more in the comfort and quality of life of the VAD patients. The 2 systems run completely without noise, and even if the patients have to carry 2 controllers and up to 4 batteries, they experience a higher grade of freedom and mobility.…”

Section: Discussionmentioning

confidence: 99%

“…Furthermore, because the native heart of the patients is excised and cannot serve as a short-term backup, there are few chances for successful treatment in the case of device failure. The implantation of 2 pulsatile displacement pumps for longterm biventricular support requires either an extensive operation with the creation of large pockets in the abdominal wall to contain the pump chambers (Thoratec IVAD; Thoratec Corp, Pleasanton, CA) 4 or 4 blood cannulas that penetrate the patient's skin and therefore carry an excessive risk for cannula or even mediastinal infection (Berlin Heart Excor, Berlin Heart GmbH, Berlin, Germany; Thoratec BVAD, Thoratec Corp; Abiocor, Abiomed Inc, Danvers, MA).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Biventricular Circulatory Support With Two Miniaturized Implantable Assist Devices

et al. 2011

View full text Add to dashboard Cite

Background-Up to 30% of patients with end-stage heart failure experience biventricular failure that requires biventricular mechanical support. For these patients, only bulky extracorporeal or implantable displacement pumps or the total artificial heart have been available to date, which enables only limited quality of life for the patients. It was our goal to evaluate a method that would allow the use of 2 implantable centrifugal left ventricular assist devices as a biventricular assist system. Methods and Results-Seventeen patients have been implanted with 2 HeartWare HVAD pumps, 1 as a left ventricular assist device and 1 as a right ventricular assist device. Seventy-seven percent of the patients had idiopathic dilated or ischemic cardiomyopathy. Their age ranged from 29 to 73 years (mean 51.8Ϯ14.5 years), and 11 (64.7%) received intravenous catecholamine support preoperatively. The right ventricular assist device pump was implanted into the right ventricular free wall. The afterload of this pump was artificially increased by local reduction of the outflow graft diameter, and the effective length of its inflow cannula was reduced by the addition of two 5-mm silicon suture rings to the original HVAD implantation ring. All right ventricular assist device devices could be operated in appropriate speed ranges and delivered a flow of between 3.0 and 5.5 L/min. Thirty-day survival was 82%, and 59% of the patients could be discharged home after recovering from the operation. There was no clinically relevant hemolysis in any of the patients. Conclusions-Two HeartWare HVAD pumps can be used as a biventricular assist system. This implantable biventricular support gives the patients more comfort and mobility than usual biventricular ventricular assist devices with large and noisy displacement pumps. (Circulation. 2011;124[suppl 1]:S179 -S186.)

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

Biventricular Circulatory Support With Two Miniaturized Implantable Assist Devices

et al. 2011

View full text Add to dashboard Cite

show abstract

“…The most common solutions, incorporated with the construction of the VAD, provided a partial answer to the problem by detecting the full-filling and complete-empty state of the blood chamber of the prosthesis (magnetic and optical methods) (Reichenbach et al, 2001;Franco, Verrier, 2003). They allow a proper full/empty operation -not allowing a fluent alteration of the CO.…”

Section: The Actual State Of the Researches In Terms Of The Monitorinmentioning

confidence: 99%

“…They allow a proper full/empty operation -not allowing a fluent alteration of the CO. In other cases indirect measurements utilizing the air flow in the air duct, as well as the blood flow in the blood ducts are used but they require periodic scaling realized by means of other methods (Reichenbach et al, 2001). In the case of blood flow-rate measurements, the most common solutions due to their noninvasiveness, are ultrasound flow-rate meters.…”

Section: The Actual State Of the Researches In Terms Of The Monitorinmentioning

confidence: 99%

Acoustic System of Determining the Instantaneous Volume of the Blood Part of the Ventricular Assist Device POLVAD-EXT

Konieczny¹,

Pustelny²,

Opilski³

et al. 2015

Archives of Acoustics

View full text Add to dashboard Cite

The paper presents the results of investigations concerning the noninvasive method of estimating the actual volume of the blood chamber of the POLVAD-EXT type ventricular assist device (VAD) during its operation. The proposed method is based on the principle of Helmholtz's acoustic resonance. Both the theory, main stages of the development of the measurement method as well as the practical implementation of the proposed method in the physical model of the POLVAD-EXT device are dealt with. The paper contains the results of static measurements by means of the proposed method (conducted at the Department of Optoelectronics, Silesian University of Technology) as well as the dynamic measurements taken at the Foundation of Cardiac Surgery Development (Zabrze, Poland) with the professional model of the human cardiovascular system. The results of these measurements prove that the proposed method allows to estimate the actual blood chamber volume with uncertainties below 10%.

show abstract

“…Además de lo anterior, se logró miniaturizar la bomba, existiendo la posibilidad de instalar ésta en posición intracorpórea (Thoratec IVAD ® ) 18 .…”

Section: Bombas Pulsátiles De Ubicación Extracorpóreaunclassified

Estado actual de los sistemas de soporte circulatorio mecánico: State of the art

2006

Rev. méd. Chile

View full text Add to dashboard Cite

Circulatory mechanical support. State of the artDespite advances in medical treatment, the prognosis of advanced heart failure remains poor. The number of hospitalizations for heart failure exacerbations continues to increase and most patients will ultimately die of complications related to heart failure. Implantable left ventricular assist devices (LVAD) are currently in use throughout the world with increasing frequency. This paper is a comprehensive review about mechanical support, focusing on a general description of the differents LVAD, complications and mortality (Rev Méd Chile 2006; 134: 1330-37 a insuficiencia cardíaca (IC) es una de las principales causas de mortalidad y hospitalización, se estima que su prevalencia se incrementará con el envejecimiento de la población. Pese al avance en la terapia farmacológica, el trasplante es una alternativa probada, pero restringida por la disponibilidad de donantes, observándose una elevada mortalidad en lista de espera de alrededor de 16% al año 1 . A lo anterior se suma el que en casos de IC aguda, muchas veces no se logra el trasplante dado lo crítico de la situación o a contraindicaciones. Es por estos motivos que los sistemas de soporte circulatorio mecánico (SSCM) han crecido en importancia, primordialmente como puente al trasplante, para lograr recuperación de una IC aguda, y en forma preliminar como terapia definitiva. Nuestro centro inició, a mediados de 2003, un programa de soporte circulatorio de corto plazo (ABIOMED BVS 5000). Este sistema ha sido utilizado en 4 pacientes, logrando el trasplante en tres de ellos. Esta experiencia inicial nos motivó a revisar el estado actual de los SSCM. CRITERIOS DE SELECCIÓN DE PACIENTESPARA ASISTENCIA VENTRICULAR Estos dispositivos son utilizados en pacientes con IC grave refractaria a terapia habitual y que no han tenido respuesta al uso del balón de contrapulsación (BCIA) y drogas vasoactivas (DVA). En general, se utilizan criterios similares a los usados para el ingreso a lista de trasplante cardíaco de urgencia. La presencia de disfunción hepática o renal, determinada por la IC y que potencialmente es reversible, no contraindica su uso. Del punto de vista hemodinámico, se utilizan valores referenciales para plantear el uso de SSCM como un índice cardíaco de 2 L/min/m 2 , presión arterial sistólica <90 mmHg y con capilares pulmonares mayores de 20 mmHg. INDICACIONES DEL USO DE SOPORTE VENTRICULAR1. Shock cardiogénico postcardiotomía: La necesidad de soporte circulatorio postcirugía cardíaca es relativamente baja (0,2 a 1%) 2 . Es más frecuente en cirugías de revascularización coronaria con disfunción ventricular significativa. El objetivo es

show abstract

A versatile intracorporeal ventricular assist device based on the Thoratec VAD system

Cited by 33 publications

References 18 publications

Biventricular Circulatory Support With Two Miniaturized Implantable Assist Devices

Biventricular Circulatory Support With Two Miniaturized Implantable Assist Devices

Acoustic System of Determining the Instantaneous Volume of the Blood Part of the Ventricular Assist Device POLVAD-EXT

Estado actual de los sistemas de soporte circulatorio mecánico: State of the art

Contact Info

Product

Resources

About